ASCO 2023

Highlights of Fred Hutch Presentations at ASCO

Oral Abstract  |  Poster Discussion Session  |  Poster Session  |  Publication Only

Oral Abstract

Oral Abstract: Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.
Presenter: Eric Chow
Monday, June 5, 9:00 a.m. - 9:12 a.m. (CT)

Oral Abstract: Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).
Presenter: Shailender Bhatia
Monday, June 5, 5:00 p.m. - 5:12 p.m. (CT)

Oral Abstract: A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).
Presenter: Noam Kopmar
Friday, June 2, 3:12 p.m. - 3:24 p.m. (CT)

Oral Abstract: Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
Presenter: Megan Othus
Sunday, June 4, 10:49 a.m. - 11:01 a.m. (CT)

Oral Abstract: Risk of early mortality in patients with cancer experiencing adverse financial events.
Presenter: Hiba Khan
Tuesday, June 6, 9:00 a.m. - 9:12 a.m. (CT)

Poster Discussion Session

Poster Discussion Session: A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
Presenter: Lee Cranmer
Saturday, June 3, 4:30 p.m. - 6:00 p.m. (CT)

Poster Discussion Session: Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).
Presenter: Petros Grivas
Saturday, June 3, 3:00 p.m. - 4:30 p.m. (CT)

Poster Discussion Session: Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.
Presenter: Cristina Rodriguez
Monday, June 5, 4:30 p.m. - 6:00 p.m. (CT)

Poster Discussion Session: Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
Presenter: Emily Liang
Monday, June 5, 1:15 p.m. - 2:45 p.m. (CT)

Poster Discussion Session: The impact of adverse financial events on healthcare utilization and treatment costs at the end of life.
Presenter: Chipo Kwendakwema
Saturday, June 3, 4:30 p.m. - 6:00 p.m. (CT)

Poster Session

Poster Session: Preclinical testing of FOLR1-CAR T cells against osteosarcoma (OS).
Presenter: Michelle Choe
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
Presenter: Carrie Ho
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Evaluation of cardiac failure and recovery in acute myelogenous leukemia.
Presenter: Matthew Wu
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: The somatic mutation profile of breast cancer in Uganda.
Presenter: Manoj Menon
Sunday, June 4, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
Presenter: Ruben Raychaudhuri
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
Presenter: Ruben Raychaudhuri
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Presenter: Laura Samples
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.
Presenter: Joseph Unger
Monday, June 5, 1:15 p.m. - 4:15 p.m. (CT)

Poster Session: Impact of the COVID-19 pandemic on insurance transitions among commercially insured cancer patients in Washington state.
Presenter: Scott Ramsey
Saturday, June 3, 1:15 p.m. - 4:15 p.m. (CT)

Poster Session: Molecular testing utilization in patients with advanced non-small cell lung cancer (NSCLC) in Washington (WA) state.
Presenter: Veena Shankaran
Saturday, June 3, 1:15 p.m. - 4:15 p.m. (CT)

Poster Session: Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.
Presenter: Danielle Kirkey
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Use of germline testing in patients with prostate, pancreatic, or ovarian cancer in Washington (WA) state.
Presenter: Veena Shankaran, Qin Sun
Saturday, June 3, 1:15 p.m. - 4:15 p.m. (CT)

Poster Session: Differential responses to systemic therapy among patients who are financially fragile and receiving Medicaid: Results from ePRO and biometric monitoring study.
Presenter: Scott Ramsey
Monday, June 5, 1:15 p.m. - 4:15 p.m. (CT)

Poster Session: Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.
Presenter: Sarah Psutka
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Identification of factors to predict low risk febrile neutropenia admissions in patients with acute myeloid leukemia (AML) following intensive chemotherapy.
Presenter: Khushboo Pal
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study.
Presenter: Bart Scott
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.
Presenter: Andrew Coveler
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
Presenter: Ryan Lynch
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Poster Session: Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Presenter: Rafee Talukder
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)

Publication Only

Publication Only: Effect of change in ECOG performance status at diagnosis and relapse in patients with acute myeloid leukemia.
Presenter: Michelle Zhang

Publication Only: Association between symptoms and health-related quality of life in patients with cancer with prior or ongoing immune checkpoint inhibitor therapy exposure.
Presenter: Salene Jones

Publication Only: Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The Immunowave study.
Presenter: Anissa Chan

Publication Only: Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.
Presenter: Courtney Daum

Publication Only: Pilot trial of the feasibility, acceptability, and potential efficacy of a pain management intervention adapted for older adults with cancer in rural settings.
Presenter: Megan Shen

Publication Only: Comparison of conventional clinical models and a multigene assay to assess DCIS risk in a prospective single center study.
Presenter: Loise Wairiri

Publication Only: Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients.
Presenter: Natalie Uy

Publication Only: The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.
Presenter: Jessica Hawley

Publication Only: Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.
Presenter: Evan Yu